These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
199 related articles for article (PubMed ID: 34789416)
21. Characteristics of the 24-h ambulatory blood pressure monitoring in patients with Parkinson's disease - the SFC BP multicentre study in China. Chen SW; Wang YK; Dou RH; Xie XY; Hu YB; Ding N; Zhang GH; Jing HF; Zhao WD; Xue Y; Li Y; Wang G J Hypertens; 2020 Nov; 38(11):2270-2278. PubMed ID: 32649630 [TBL] [Abstract][Full Text] [Related]
22. The potential significance of hepcidin evaluation in progressive supranuclear palsy. Alster P; Otto-Ślusarczyk D; Wiercińska-Drapało A; Struga M; Madetko-Alster N Brain Behav; 2024 Jun; 14(6):e3552. PubMed ID: 38953731 [TBL] [Abstract][Full Text] [Related]
23. The pattern of verbal, visuospatial and procedural learning in Richardson variant of progressive supranuclear palsy in comparison to Parkinson's disease. Sitek EJ; Wieczorek D; Konkel A; Dąbrowska M; Sławek J Psychiatr Pol; 2017 Aug; 51(4):647-659. PubMed ID: 28987055 [TBL] [Abstract][Full Text] [Related]
24. Clinical progression of progressive supranuclear palsy: impact of trials bias and phenotype variants. Street D; Malpetti M; Rittman T; Ghosh BCP; Murley AG; Coyle-Gilchrist I; Passamonti L; Rowe JB Brain Commun; 2021; 3(3):fcab206. PubMed ID: 34541533 [TBL] [Abstract][Full Text] [Related]
33. Association of Progressive Supranuclear Palsy Rating Scale with Progressive Supranuclear Palsy Quality of Life Scale. Pantelyat A; Higginbotham L; Rosenthal L; Lanham D; Nesspor V; AlSalihi M; Bang J; Wang J; Albert M Neurodegener Dis; 2020; 20(4):139-146. PubMed ID: 33789283 [TBL] [Abstract][Full Text] [Related]
34. Montreal Cognitive Assessment (MoCA) and Mini-Mental State Examination (MMSE) performance in progressive supranuclear palsy and multiple system atrophy. Fiorenzato E; Weis L; Falup-Pecurariu C; Diaconu S; Siri C; Reali E; Pezzoli G; Bisiacchi P; Antonini A; Biundo R J Neural Transm (Vienna); 2016 Dec; 123(12):1435-1442. PubMed ID: 27334897 [TBL] [Abstract][Full Text] [Related]
35. Rate of decline in progressive supranuclear palsy. Litvan I; Kong M Mov Disord; 2014 Apr; 29(4):463-8. PubMed ID: 24615741 [TBL] [Abstract][Full Text] [Related]
36. Can the frontal assessment battery (FAB) differentiate bradykinetic rigid syndromes? Relation of the FAB to formal neuropsychological testing. Paviour DC; Winterburn D; Simmonds S; Burgess G; Wilkinson L; Fox NC; Lees AJ; Jahanshahi M Neurocase; 2005 Aug; 11(4):274-82. PubMed ID: 16093228 [TBL] [Abstract][Full Text] [Related]
37. Hypokinesia without decrement distinguishes progressive supranuclear palsy from Parkinson's disease. Ling H; Massey LA; Lees AJ; Brown P; Day BL Brain; 2012 Apr; 135(Pt 4):1141-53. PubMed ID: 22396397 [TBL] [Abstract][Full Text] [Related]
38. Gait Analysis in Progressive Supranuclear Palsy Phenotypes. Picillo M; Ricciardi C; Tepedino MF; Abate F; Cuoco S; Carotenuto I; Erro R; Ricciardelli G; Russo M; Cesarelli M; Barone P; Amboni M Front Neurol; 2021; 12():674495. PubMed ID: 34177779 [TBL] [Abstract][Full Text] [Related]
39. Clinical Utility of Tectal Plate Measurements on Magnetic Resonance Imaging in Progressive Supranuclear Palsy. Amrami A; Singh NA; Ali F; Pham NTT; Stephens YC; Josephs KA; Whitwell JL Mov Disord; 2024 Aug; 39(8):1402-1407. PubMed ID: 38586905 [TBL] [Abstract][Full Text] [Related]
40. Cognitive deficits in progressive supranuclear palsy on the Repeatable Battery for the Assessment of Neuropsychological Status. Duff K; McDermott D; Luong D; Randolph C; Boxer AL J Clin Exp Neuropsychol; 2019 Jul; 41(5):469-475. PubMed ID: 30712468 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]